Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06290388 · ClinicalTrials.gov registry record · Phase 1
Study of 23ME-01473 in Patients With Advanced Solid Malignancies
A Phase 1 study, sponsored by 23andMe.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT06290388: Clinical Trial Phase 1 study, sponsored by 23andMe.
NCT06290388 is a Phase 1 study that was terminated before completion, run by 23andMe. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06290388, a Phase 1 study, was terminated before completion, sponsored by 23andMe.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a first-in-human open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-01473 given by intravenous infusion in participants with advanced solid cancers who have progressed or are intolerant of available standard therapies.
Interventions
- DRUG 23ME-01473
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-03-07 |
| Est. Completion | 2024-11-10 |
| Phase | Phase 1 |
Why NCT06290388 stopped before completion
NCT06290388 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which 23ME-01473 is the first listed.
NCT06290388 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06290388 about?
NCT06290388 is a clinical study titled "Study of 23ME-01473 in Patients With Advanced Solid Malignancies". This is a first-in-human open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-01473 given by intravenous infusion in participants with advanced solid cancers who have progressed or are intolerant of available standard th...
What is the current status of trial NCT06290388?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2024-03-07. Estimated completion is 2024-11-10.
What interventions are being tested in trial NCT06290388?
The interventions under investigation include: 23ME-01473 (DRUG).
Who is sponsoring clinical trial NCT06290388?
This trial is sponsored by 23andMe, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06290388's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI